Tuesday saw researchers from the United States of America saying that drug manufacturer Wyeth brought in ghostwriters in order to promote the advantages and downplay the disadvantages of hormone replacement therapy in a number of articles that are published in medical periodicals.

Georgetown University Medical Center's Dr. Adriane Fugh-Berman, of Washington, and contemporaries evaluated a number of reviews and comments written by ghostwriters that are printed in medical journals and other periodical supplements where a lot of them have made use of credentials from legal hearings.

They said that Wyeth, which is at present possessed by Pfizer, offered $25,000 to a medical communication firm named DesignWrite, so as to ghostwrite articles relating to clinical studies, which also included four evaluating low-dose, Prempro, which is the firm's amalgamated estrogen-progestin treatment.

As informed by the team, the articles were written with the intention to ease out worries relating to hormone replacement therapy, which was deemed to have raised the chances of developing breast cancer and also, to help the groundless idea that the drugs offered protection against heart problems.

DesignWrite was as well offered work to write 20 reviews concerning the drug at a price tag of $20,000 each.

Report faced a challenge from Pfizer, stating that Fugh-Berman was an expert, who had been paid for the plaintiffs in a related case.